2009•NeurologyOpen access

Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons

Lisa B. Hoffman, James M. Schmeidler, Gershon T. Lesser, Michal Schnaider Beeri, Dushyant P. Purohit, Hillel T. Grossman, Varham Haroutunian

Open full text 161 citations

Abstract

Objective: To test the hypothesis that use of antihypertensive medication is associated with lower Alzheimer disease (AD) neuropathology. Methods: This was a postmortem study of 291 brains limited to those with normal neuropathology or with uncomplicated AD neuropathology (i.e., without other dementia-associated neuropathology) in persons with or without hypertension (HTN) who were and were not treated with antihypertensive medications. Neuritic plaque (NP) and neurofibrillary tangle (NFT) densities, quantified in selected brain regions according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropathologic criteria, with additional cortical NP counts, yielded 24 neuropathologic regional measures or summaries. Medicated hypertension (HTN-med; n = 77), nonmedicated HTN (HTN-nomed; n = 42), and non-HTN (no-HTN; n = 172) groups were compared by analyses of variance. Results: The HTN-med group had significantly less neuropathology than the no-HTN group. The no-HTN group averaged over 50% higher mean NP and NFT ratings, and double the mean NP count, of the HTN-med group. The HTN-nomed group had significantly more neuropathology than the HTN-med group, but not significantly less than the no-HTN group. Conclusions: There was substantially less Alzheimer disease (AD) neuropathology in the medicated hypertension group than the nonhypertensive group, which may reflect a salutary effect of antihypertensive medication against AD-associated neuropathology. AD= : Alzheimer disease; ANCOVA= : analysis of covariance; ANOVA= : analysis of variance; BB= : β-blockers; BMI= : body mass index; CCB= : calcium channel blockers; CDR= : Clinical Dementia Rating scale; CERAD= : Consortium to Establish a Registry for Alzheimer’s Disease; DBP= : diastolic blood pressure; EC= : entorhinal cortex; HAAS= : Honolulu Asia Aging Study; Hipp= : hippocampus; HTN= : hypertension; IPL= : inferior parietal lobule; JHH= : Jewish Home and Hospital; MFG= : midfrontal gyrus; MSSM= : Mount Sinai School of Medicine; NFT= : neurofibrillary tangle; NH= : nursing homes; NP= : neuritic plaque; OC= : occipital calcarine cortex; OFG= : orbital frontal cortex; SBP= : systolic blood pressure; STG= : superior temporal gyrus.

About this research paper

What this paper is about

Objective: To test the hypothesis that use of antihypertensive medication is associated with lower Alzheimer disease (AD) neuropathology. Methods: This was a postmortem study of 291 brains limited to those with normal neuropathology or with uncomplicated AD neuropathology (i.e., without other dementia-associated neuropathology) in persons with or without hypertension (HTN) who were and were not treated with antihypertensive medications. Neuritic plaque (NP) and neurofibrillary tangle (NFT) densities, quantified in selected brain regions according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropathologic criteria, with additional cortical NP counts, yielded 24 neuropathologic regional measures or summaries. Medicated hypertension (HTN-med; n = 77), nonmedicated HTN (HTN-nomed; n = 42), and non-HTN (no-HTN; n = 172) groups were compared by analyses of variance. Results: The HTN-med group had significantly less neuropathology than the no-HTN group. The no-HTN group averaged over 50% higher mean NP and NFT ratings, and double the mean NP count, of the HTN-med group. The HTN-nomed group had significantly more neuropathology than the HTN-med group, but not significantly less than the no-HTN group. Conclusions: There was substantially less Alzheimer disease (AD) neuropathology in the medicated hypertension group than the nonhypertensive group, which may reflect a salutary effect of antihypertensive medication against AD-associated neuropathology. AD= : Alzheimer disease; ANCOVA= : analysis of covariance; ANOVA= : analysis of variance; BB= : β-blockers; BMI= : body mass index; CCB= : calcium channel blockers; CDR= : Clinical Dementia Rating scale; CERAD= : Consortium to Establish a Registry for Alzheimer’s Disease; DBP= : diastolic blood pressure; EC= : entorhinal cortex; HAAS= : Honolulu Asia Aging Study; Hipp= : hippocampus; HTN= : hypertension; IPL= : inferior parietal lobule; JHH= : Jewish Home and Hospital; MFG= : midfrontal gyrus; MSSM= : Mount Sinai School of Medicine; NFT= : neurofibrillary tangle; NH= : nursing homes; NP= : neuritic plaque; OC= : occipital calcarine cortex; OFG= : orbital frontal cortex; SBP= : systolic blood pressure; STG= : superior temporal gyrus.

Why it matters

OpenAlex reports 161 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective: To test the hypothesis that use of antihypertensive medication is associated with lower Alzheimer disease (AD) neuropathology. Methods: This was a postmortem study of 291 brains limited to those with normal neuropathology or with uncomplicated AD neuropathology (i.e., without other dementia-associated neuropathology) in persons with or without hypertension (HTN) who were and were not treated with antihypertensive medications. Neuritic plaque (NP) and neurofibrillary tangle (NFT) densities, quantified in selected brain regions according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropathologic criteria, with additional cortical NP counts, yielded 24 neuropathologic regional measures or summaries. Medicated hypertension (HTN-med; n = 77), nonmedicated HTN (HTN-nomed; n = 42), and non-HTN (no-HTN; n = 172) groups were compared by analyses of variance. Results: The HTN-med group had significantly less neuropathology than the no-HTN group. The no-HTN group averaged over 50% higher mean NP and NFT ratings, and double the mean NP count, of the HTN-med group. The HTN-nomed group had significantly more neuropathology than the HTN-med group, but not significantly less than the no-HTN group. Conclusions: There was substantially less Alzheimer disease (AD) neuropathology in the medicated hypertension group than the nonhypertensive group, which may reflect a salutary effect of antihypertensive medication against AD-associated neuropathology. AD= : Alzheimer disease; ANCOVA= : analysis of covariance; ANOVA= : analysis of variance; BB= : β-blockers; BMI= : body mass index; CCB= : calcium channel blockers; CDR= : Clinical Dementia Rating scale; CERAD= : Consortium to Establish a Registry for Alzheimer’s Disease; DBP= : diastolic blood pressure; EC= : entorhinal cortex; HAAS= : Honolulu Asia Aging Study; Hipp= : hippocampus; HTN= : hypertension; IPL= : inferior parietal lobule; JHH= : Jewish Home and Hospital; MFG= : midfrontal gyrus; MSSM= : Mount Sinai School of Medicine; NFT= : neurofibrillary tangle; NH= : nursing homes; NP= : neuritic plaque; OC= : occipital calcarine cortex; OFG= : orbital frontal cortex; SBP= : systolic blood pressure; STG= : superior temporal gyrus.

Key concepts: Neuropathology, Medicine, Dementia, Disease, Alzheimer's disease, Internal medicine, Senile plaques

Related papers

Back to paper searchBrowse research topicsOriginal source
Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons — Research Paper | ScholarLens